Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib

Deep molecular response in chronic myeloid leukemia (CML) patients treated with imatinib is a prerequisite for possible discontinuation. We identify clinico-biologic features linked with the probability of reaching MR4.5 (BCR-ABL/ABL ≤ 0.0032% IS) as a stable response (confirmed on two or more conse...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Oncotarget
Главные авторы: Breccia, Massimo, Molica, Matteo, Colafigli, Gioia, Massaro, Fulvio, Quattrocchi, Luisa, Latagliata, Roberto, Mancini, Marco, Diverio, Daniela, Guarini, Anna, Alimena, Giuliana, Foà, Robin
Формат: Artigo
Язык:Inglês
Опубликовано: Impact Journals LLC 2017
Предметы:
Research Paper
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC5800922/
https://ncbi.nlm.nih.gov/pubmed/29484130
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.23691
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы